This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetics of AZD7295 Capsules

This study has been completed.
Information provided by:
Arrow Therapeutics Identifier:
First received: March 30, 2010
Last updated: August 6, 2010
Last verified: August 2010
This is a pharmacokinetics (PK) and safety study of AZD7295 in healthy volunteers.

Condition Intervention Phase
Healthy Drug: AZD7295 Drug: Placebo comparator Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-Blind, Placebo-Controlled Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD7295 Capsules in Healthy Volunteers

Further study details as provided by Arrow Therapeutics:

Primary Outcome Measures:
  • Pharmacokinetics of AZD7295 capsules [ Time Frame: 0-72h after each dose ]
    PK parameters of AZD7295 will be measured after single and repeated doses (AUC, Cmax, t1/2)

Secondary Outcome Measures:
  • Safety and tolerability of AZD7295 capsules [ Time Frame: 0-72h after each dose ]
    Safety and tolerability of AZD7295 will be assessed after single and repeated doses (adverse events, ECGs, vital signs, safety laboratory tests)

Enrollment: 12
Study Start Date: March 2010
Study Completion Date: August 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZD7295 Drug: AZD7295
Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
Placebo Comparator: Matched placebo Drug: Placebo comparator
Placebo capsules


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male or female volunteers, aged 18-65 years.

Exclusion Criteria:

  • Previous exposure to AZD7295, clinically relevant disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01097408

United Kingdom
Quotient Clinical Research
Nottingham, United Kingdom
Sponsors and Collaborators
Arrow Therapeutics
Principal Investigator: Jo Collier, Mb ChB Quotient Clinical Research
  More Information

Responsible Party: Liz Clark, Arrow Therapeutics Identifier: NCT01097408     History of Changes
Other Study ID Numbers: HCV689-105
Study First Received: March 30, 2010
Last Updated: August 6, 2010 processed this record on August 18, 2017